Loading data for AXSM — first visit, this takes a few seconds.

알림

Axsome Therapeutics Inc. (AXSM)

NasdaqGM: AXSM · 실시간 가격 · USD

199.02

-7.25 (-3.51%)

종가 기준: Aug 28, 2026, 8:00 PM

199.00

-0.01%

애프터마켓: 7:48 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-3.51% (1D)

데이터 없음

매수호가	170.52
시가총액	10.42B
매출 (ttm)	776.57M
순이익 (ttm)	-191.64M
	0.73
	-3.75
	n/a
	39.54
P/B (ttm)	124.93
P/S (ttm)	13.42
실적 발표일	Nov 2, 2026

매도호가	259.2
거래량	441,176
평균 거래량 (20일)	861,974
시가	205.70
전일 종가	206.27
일중 범위	199.00 - 205.70
52주 범위	112.90 - 260.19
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

AXSM 소개

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (so...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Nov 19, 2015

직원 수 1,346

상장 거래소 NasdaqGM

티커 AXSM

웹사이트 https://www.axsome.com

전체 기업 정보

재무 실적

2025년 Axsome Therapeutics의 매출은 638.5M로, 전년 385.69M 대비 65.55% 증가했습니다. 순이익은 -183.17M로, -36.22% 감소했습니다.

재무제표

어닝 서프라이즈

Axsome Therapeutics가 Aug 10, 2026에 분기 실적을 발표했습니다:

매출 $191.2M 예상치 하회 $0, 및 57.42% 전년 대비 성장.
EPS -0.99 예상치 하회 -0.21, 및 -2.06% 전년 대비 감소.

다음 실적 발표

Axsome Therapeutics Inc.의 실적 발표 예정일은 Nov 2, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

6일 전 · Motley Fool

Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run

The company has also crushed broader equities over the past five years.

2주 전 · Zacks

Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.

2주 전 · Simply Wall St.

Axsome Therapeutics (AXSM) Shares Just Climbed, So What Is Driving Attention Now?

Axsome Therapeutics earnings event and why it matters Axsome Therapeutics (AXSM) just reported second quarter 2026 results, with revenue of US$218.38 million and a net loss of US$51.31 million. Earnin...

2주 전 · Simply Wall St.

Does Axsome Therapeutics (AXSM) Look Fairly Valued At This Price?

Axsome Therapeutics has delivered a very large 5 year return while the current valuation checks point to a stock that now looks closer to fairly priced than clearly cheap. The market has rewarded the ...

2주 전 · Stocktwits

AXSM Stock Advances On CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030

The FDA has already accepted the company’s application seeking the greenlight for AXS-12.

2 페이지 중 1

Axsome Therapeutics Inc. (AXSM)